Search
Now showing items 31-40 of 61
Evaluation of six tumor markers in patients with carcinoma of unknown primary
(1994)
We have retrospectively evaluated six serum tumor markers in 85 patients with carcinoma of unknown primary. The serum levels of carcinoembryonic antigen (CEA), CA 19‐9, CA 15‐3, CA 125, β‐chorionic gonadotropin (β‐HCG) and ...
A retrospective analysis of serum CA 15-3 concentrations in patients with localised or metastatic renal cancer and its impact on prognosis and follow-up. A single-centre experience
(2002)
Background. Monitoring patients with renal cancer for recurrence or progression is ineffective, inconvenient and costly. We conducted a retrospective analysis of serum CA 15-3 concentrations in a single-centre patient ...
p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: A ten-year follow-up study
(1998)
The aim of this study was the evaluation of p53/MDM-2 protein overexpression in different subtypes of human sarcomas, and their correlation with proliferative activity and patient outcome. We selected 40 cases of human ...
Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study
(2001)
The clinical relevance of quantitative assessment of tumor-tissue expression of the bcl-2 protein in operated stage II breast cancer was investigated in this study. Thirty-five cases were studied by immunohistochemistry ...
Bcl2 and p53 protein expression in metastatic carcinoma of unknown primary origin: Biological and clinical implications. A Hellenic co-operative oncology group study
(1998)
We have previously shown that metastatic carcinomas of unknown primary site overexpress several tumor markers as well as the products of the oncogenes c-myc, ras and c-erbB2. We analysed the tissue expression of the protein ...
Overexpression of C-myc, ras and C-erb B-2 oncoproteins in carcinoma of unknown primary origin
(1995)
The role of oncogenes in carcinoma of unknown primary site (CUP) has not yet been elucidated. In the present study the expression of the c-myc p62, ras p21 and c-erb B p185 oncoproteins were studied by a 3-step immunoperoxidase ...
Epithelial ovarian cancer in Greece: A retrospective study of 1,791 patients by the hellenic cooperative oncology group (HeCOG)
(2009)
Background: The aim of this retrospective study was to present the epidemiological, pathological and clinical characteristics and treatment results of Greek women with epithelial ovarian cancer (EOC). Patients and Methods: ...
The clinical significance of bcl-2 overexpression in breast cancer patients - A retrospective study with long term follow up
(2001)
We examined by immunohistochemistry the expression of the bcl-2 protein in sixty-eight cases of operated breast carcinoma patients (stage I, II and III) and correlated the findings with the prognosis. In 38.3% of the cases ...
Oxaliplatin (eloxatin™) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma
(2005)
Therapeutic options for metastatic insular thyroid carcinoma (ITC) are very limited. We present the case of a 39-year-old woman with refractory metastatic ITC who responded to oxaliplatin plus irinotecan chemotherapy. She ...
Matrix metalloproteinases in carcinoma of unknown primary
(2005)
BACKGROUND. The purpose was to study proteolysis-related molecules, matrix metalloproteinase-2 (MMP-2) and MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1), in carcinoma of unknown primary (CUP). METHODS. ...